In conclusion, for patients with a high clinical suspicion of CML, it is necessary to re-screen for atypical BCR::ABL fusion genes in patients who are negative by conventional tests. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.